

Full title: Elranatamab Fixed Dosing: A Safe, Effective, and Convenient Dosing Approach

Mohamed Elmeliegy¹, Pooneh Soltantabar¹, Jennifer Hibma², Olivia Ashman³, Diane Wang¹, Hoi-Kei Lon¹

¹Oncology Research and Development, Pfizer, Inc., San Diego, CA, USA; ² Pfizer Research and Development, Pfizer, Inc., San Diego, CA, USA; ³ Pfizer Global Medical Strategy, Pfizer Ltd, London UK

Corresponding author:


Hoi-Kei Lon, PhD

Oncology Research and Development, Pfizer Inc, San Diego, CA, USA

ceci.lon@pfizer.com


Supplementary Information

Supplemental Figure 1: Correlation between predose and average elranatamab concentrations



Q, quartile.

Supplemental Figure 2: Elranatamab maximum concentration of elranatamab within 24 hours of first dose by body weight quartile



Boxplot showing the median and 25%/75% quartiles with whiskers to the last point within 1.5 times interquartile range.

C_{max}, maximum concentration; Q, quartile.